Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in Boston, Massachusetts. The company focuses on the discovery and development of dual-action antibody therapeutics designed to treat complex oncological conditions and solid tumors. Its proprietary pipeline features targeted immunotherapy candidates that combine tumor-targeting antibodies with immune-activating agents to enhance patient treatment response. Principal revenue is currently earned through private financing, research grants, and clinical development collaborations. Bicara Therapeutics Inc is publicly traded on the Nasdaq Stock Market.
6 of the funds FundTelligence covers report a position in Bicara Therapeutics.
- Legal name
- Bicara Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Bicara Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.79 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 0.45 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 0.38 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.12 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)